Literature DB >> 11344175

Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency.

A Colao1, C di Somma, A Cuocolo, L Spinelli, N Tedesco, R Pivonello, D Bonaduce, M Salvatore, G Lombardi.   

Abstract

Adult GH deficiency (GHD) is associated with increased cardiovascular morbidity and mortality due to unfavorable lipid profile, hyperfibrinogenemia, and impairment of cardiac performance. This prospective controlled cohort study evaluated the effects of 12-month GH replacement on lipid profile, fibrinogen levels, cardiac mass by echocardiography, and performance by equilibrium radionuclide angiography. To this end we studied 20 patients (11 men and 9 women, aged 19-40 yr), 10 with childhood-onset (co-) and 10 with adult-onset (ao-) disease, and 20 sex- and age-matched healthy subjects. At study entry, insulin-like growth factor I (IGF-I; P < 0.0001) and high density lipoprotein (HDL) cholesterol (P < 0.0001) levels, left ventricular mass index (LVMi; P < 0.0001), ejection fraction (LVEF) at rest (P = 0.001) and at peak exercise (P < 0.0001), peak ejection rate (P = 0.005), and exercise duration (P < 0.0001) and capacity (P = 0.002) were lower, whereas total cholesterol (P = 0.02), triglycerides (P = 0.003), and fibrinogen (P = 0.005) levels were higher in patients than in controls. After 12 months, increases in IGF-I (P < 0.0001) and HDL cholesterol levels (P = 0.04), LVMi (P < 0.0001), LVEF at peak exercise (P < 0.0001), and exercise duration (P = 0.009) and capacity (P = 0.003) and decreases in total cholesterol (P < 0.0001), low density lipoprotein cholesterol (P < 0.0001), triglycerides (P < 0.0001), and fibrinogen (P = 0.01) levels were found in all patients, without any difference between co- and ao-GHD. At the end of treatment, however, total cholesterol, triglycerides, and fibrinogen levels were still higher, and HDL cholesterol levels, IGF-I levels, and LVEF at rest and at peak exercise were lower in patients than in controls. In conclusion, GH replacement for 12 months significantly improved lipid profile, decreased fibrinogen levels, and increased LVMi and LVEF in young adults with co- or ao-GHD. However, lipid profile, fibrinogen levels, and systolic function remained abnormal compared with those in age- and sex-matched controls, suggesting that a longer period of GH replacement is necessary to normalize cardiovascular parameters and reverse the cardiovascular risk of these patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11344175     DOI: 10.1210/jcem.86.5.7464

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

1.  Growth hormone status predicts left ventricular mass in patients after cure of acromegaly.

Authors:  Tamara L Wexler; Ronen Durst; David McCarty; Michael H Picard; Lindsay Gunnell; Zehra Omer; Pouneh Fazeli; Karen K Miller; Anne Klibanski
Journal:  Growth Horm IGF Res       Date:  2010-07-03       Impact factor: 2.372

Review 2.  The cardiovascular system in growth hormone excess and growth hormone deficiency.

Authors:  G Lombardi; C Di Somma; L F S Grasso; M C Savanelli; A Colao; R Pivonello
Journal:  J Endocrinol Invest       Date:  2012-11-12       Impact factor: 4.256

3.  Cardiac function in growth hormone deficient patients before and after 1 year with replacement therapy: a magnetic resonance imaging study.

Authors:  Mikkel Andreassen; Jens Faber; Andreas Kjaer; Claus Leth Petersen; Lars Østergaard Kristensen
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

4.  The effect of growth hormone replacement therapy on the morphological and functional changes in the left ventricle in patients with adult-onset growth hormone deficiency.

Authors:  Anton Dlesk; Gabriel Kamenský; Ivica Lazúrová; Martin Kužma; Juraj Payer
Journal:  Wien Klin Wochenschr       Date:  2014-07-01       Impact factor: 1.704

Review 5.  Effects of low dose versus high dose human growth hormone on body composition and lipids in adults with GH deficiency: a meta-analysis of placebo-controlled randomized trials.

Authors:  Connie B Newman; John D Carmichael; David L Kleinberg
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

6.  The GH/IGF-1 Axis and Heart Failure.

Authors:  Graziella Castellano; Flora Affuso; Pasquale Di Conza; Serafino Fazio
Journal:  Curr Cardiol Rev       Date:  2009-08

7.  Structural, functional and autonomic changes in the cardiovascular system in growth hormone deficient patients.

Authors:  Doğan Erdoğan; Tufan Tükek; Ferihan Aral; Hüseyin Oflaz; Mehmet Ozaydin; Orhan Kocaman; Vakur Akkaya; Taner Gören; Senay Molvalilar
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-01       Impact factor: 1.468

8.  Effect of growth hormone treatment on diastolic function in patients who have developed growth hormone deficiency after definitive treatment of acromegaly.

Authors:  Pouneh K Fazeli; Jonathan G Teoh; Eleanor L Lam; Anu V Gerweck; Tamara L Wexler; Eliza P Teo; Brian M Russell; Ronen Durst; David McCarty; Rory B Weiner; Michael H Picard; Anne Klibanski; Karen K Miller
Journal:  Growth Horm IGF Res       Date:  2015-12-03       Impact factor: 2.372

9.  Effects of 5 years of growth hormone (GH) replacement therapy on cardiac parameters and physical performance in adults with GH deficiency.

Authors:  Maria Claudia Peixoto Cenci; Débora Vieira Soares; Luciana Diniz Carneiro Spina; Rosane Resende de Lima Oliveira Brasil; Priscila Marise Lobo; Vera Aleta Mansur; Jaime Gold; Eduardo Michmacher; Mario Vaisman; Flávia Lúcia Conceição
Journal:  Pituitary       Date:  2009-04-24       Impact factor: 4.107

Review 10.  [Growth hormone therapy in adults. Attempt to assess a decade of use].

Authors:  M Faust; C J Strasburger
Journal:  Internist (Berl)       Date:  2008-05       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.